IL147138A0 - Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation - Google Patents

Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation

Info

Publication number
IL147138A0
IL147138A0 IL14713801A IL14713801A IL147138A0 IL 147138 A0 IL147138 A0 IL 147138A0 IL 14713801 A IL14713801 A IL 14713801A IL 14713801 A IL14713801 A IL 14713801A IL 147138 A0 IL147138 A0 IL 147138A0
Authority
IL
Israel
Prior art keywords
extravasation
migration
methods
pharmaceutical compositions
cell adhesion
Prior art date
Application number
IL14713801A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL14713801A priority Critical patent/IL147138A0/xx
Publication of IL147138A0 publication Critical patent/IL147138A0/xx
Priority to IL16256402A priority patent/IL162564A0/xx
Priority to EP02793311A priority patent/EP1465656A4/en
Priority to US10/498,346 priority patent/US7951775B2/en
Priority to AU2002358967A priority patent/AU2002358967A1/en
Priority to PCT/IL2002/001014 priority patent/WO2003051272A2/en
Priority to CA002473890A priority patent/CA2473890A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14713801A 2001-12-17 2001-12-17 Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation IL147138A0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL14713801A IL147138A0 (en) 2001-12-17 2001-12-17 Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
IL16256402A IL162564A0 (en) 2001-12-17 2002-12-17 Methods and pharmaceutical compositions for gnrh-iand gnrh-iimodulation of t-cell activity, adhesion, migration and extravasat
EP02793311A EP1465656A4 (en) 2001-12-17 2002-12-17 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MODULATING T-CELL ACTIVITY THROUGH GONADOTROPHIN HORMONE I AND II (GNRH-I AND GNRH-II), ADHESION, MIGRATION AND EXTRAVASATION THEREOF
US10/498,346 US7951775B2 (en) 2001-12-17 2002-12-17 Methods and pharmaceutical compositions for GnRH-I and GnRH-II modulation of T-cell activity, adhesion, migration and extravasation
AU2002358967A AU2002358967A1 (en) 2001-12-17 2002-12-17 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
PCT/IL2002/001014 WO2003051272A2 (en) 2001-12-17 2002-12-17 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GnRH-I AND GnRH-II MODULATION OF T-CELL ACTIVITY, ADHESION, MIGRATION AND EXTRAVASATION
CA002473890A CA2473890A1 (en) 2001-12-17 2002-12-17 Methods and pharmaceutical compositions for gnrh-i and gnrh-ii modulation of t-cell activity, adhesion, migration and extravasation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14713801A IL147138A0 (en) 2001-12-17 2001-12-17 Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation

Publications (1)

Publication Number Publication Date
IL147138A0 true IL147138A0 (en) 2002-08-14

Family

ID=11075898

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14713801A IL147138A0 (en) 2001-12-17 2001-12-17 Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation

Country Status (6)

Country Link
US (1) US7951775B2 (xx)
EP (1) EP1465656A4 (xx)
AU (1) AU2002358967A1 (xx)
CA (1) CA2473890A1 (xx)
IL (1) IL147138A0 (xx)
WO (1) WO2003051272A2 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086799A1 (en) * 2003-08-11 2011-04-14 Siler-Khodr Theresa M GnRH II Analogs and Uses Thereof in the Immune System
US20100028361A1 (en) * 2006-12-19 2010-02-04 Smith Mark A Brain-derived gonadotropins and cognition
EP2473530B1 (en) * 2009-09-03 2015-04-22 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US20120004182A1 (en) * 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) * 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
AU2018209238A1 (en) 2017-01-20 2019-08-15 ISR Immune System Regulation Holding AB (publ) Novel use of known compounds- intracellular infections
US11564969B2 (en) 2017-01-20 2023-01-31 ISR Immune System Regulation Holding AB (publ) Immunorhelin compounds for intracellular infections
JP2020505379A (ja) 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー 新規化合物（イムノレリン）
US11672842B2 (en) 2017-02-22 2023-06-13 ISR Immune System Regulation Holding AB (publ) Gonadotropin-releasing hormones for use as adjuvant immunotherapeutics
CA3178806A1 (en) * 2020-04-17 2021-10-21 Corey Smith Immune cells with enhanced function

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5744450A (en) * 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
JPH08508405A (ja) * 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5593965A (en) * 1994-10-20 1997-01-14 Creighton University Anti-tumor effects of GnRH-III
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
AU720455B2 (en) 1996-04-23 2000-06-01 President And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5985901A (en) * 1997-06-05 1999-11-16 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5981550A (en) * 1997-06-05 1999-11-09 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6211224B1 (en) * 1997-10-28 2001-04-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE19814701A1 (de) 1998-04-01 1999-10-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von mit dem Gehirn assoziierten Erkrankungen, Störungen und Schädigungen
US6025366A (en) * 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6228867B1 (en) * 1998-04-02 2001-05-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
SE511005C2 (sv) 1998-07-07 1999-07-19 Laekartjaenster I Vaestsverige Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
SE514606C2 (sv) 1998-08-26 2001-03-19 Laekartjaenster I Vaestsverige Läkemedel innehållande GnRH-analoger för behandling av schizofreni
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity
US6323179B1 (en) * 1999-10-15 2001-11-27 Theresa Siler-Khodr Chicken GNRH analogs and uses thereof in regulation of fertility and pregnancy
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
CN100490205C (zh) * 2003-07-10 2009-05-20 国际商业机器公司 淀积金属硫族化物膜的方法和制备场效应晶体管的方法

Also Published As

Publication number Publication date
US20050158309A1 (en) 2005-07-21
WO2003051272A2 (en) 2003-06-26
WO2003051272A3 (en) 2004-03-18
CA2473890A1 (en) 2003-06-26
AU2002358967A1 (en) 2003-06-30
EP1465656A2 (en) 2004-10-13
EP1465656A4 (en) 2006-02-01
WO2003051272A9 (en) 2004-04-22
US7951775B2 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
IL147138A0 (en) Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2002332020A1 (en) Compositions for oral gene therapy and methods of using same
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
AU2003219788A1 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha-
HK1167332A1 (en) Pharmaceutical composition, use thereof and method for making the same
EP1539730A4 (en) NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHOD FOR THEIR APPLICATION
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
AU2003291024A1 (en) Rhodanine derivatives and pharmaceutical compositions containing them
AU2003289440A1 (en) Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
AU2003274211A1 (en) Flame-retardant composition, preparation method and use thereof
IL164424A0 (en) Novel perindopril, salt and pharmaceutical compositions containing same
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003219747A1 (en) Composition and method for coating medical devices
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU2003242369A1 (en) Powdery respiratory tonic composition
AU2003252493A1 (en) Pharmaceutical composition containing decoy and method of using the same
IL162524A0 (en) Derivatives of (pyridin-3-yl)-1-azabicycloÄ3.2.1Ü octane, their preparation and their terapeutic application
AU2003284460A1 (en) Medicinal composition
AU2002222079A1 (en) Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same
AU2001276919A1 (en) Haplotypes of the mmp13 gene
AU2003280799A1 (en) Medicinal composition
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof